Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Lease Agreements (Tables)

3 Months Ended

Mar. 31, 2021

For the three months ended March 31, 2021 and 2020, the components of our operating lease expense were as follows (in thousands):


	Three Months Ended
	March 31,
	2021		2020
Fixed operating lease expense	$	1,340	$	1,340
Variable operating lease expense		229		251
Total operating lease expense	$	1,569	$	1,591

Supplemental information related to our operating lease for the three months ended March 31, 2021 and 2020 were as follow (in thousands):


	Three Months Ended
	March 31,
	2021		2020
Cash payments included in the measurement of operating lease liabilities	$	2,496	$	2,400

For the three months ended March 31, 2021 and 2020, we have the following operating sublease information (in thousands):

The following table presents the future lease payments of our operating lease liabilities as of March 31, 2021 (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2021	$	7,586	$	(3,412)	$	4,174
2022		10,485		(4,716)		5,769
2023		877		(394)		483
Total minimum payments required	$	18,948	$	(8,522)	$	10,426